Home   |  Publications   |   Conferences    |  Join   |   Contact   | Sitemap  
                                 
 

Journal of Neurology & Neurophysiology


Open Access
 
 
 
ISSN: 2155-9562
 
 
 
home » modified-atkins-diet-and-low-glycemic-index-treatment-for-medication-resistant-epilepsy-current-trends-in-ketogenic-diet-2155-9562 Rss Feed Rss Feed
 
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
 
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business
 
 
Case Report Open Access
 
Modified Atkins Diet and Low Glycemic Index Treatment for Medication-Resistant Epilepsy: Current Trends in Ketogenic Diet
Department of Pediatrics, Shiga Medical Center for Children, Shiga, Japan Tomohiro Kumada*, Department of Pediatrics, Shiga Medical Center for Children, Shiga, Japan Tomoko Miyajima, Department of Pediatrics, Shiga Medical Center for Children, Shiga, Japan Ikuko Hiejima, Department of Pediatrics, Shiga Medical Center for Children, Shiga, Japan Fumihito Nozaki, Department of Pediatrics, Shiga Medical Center for Children, Shiga, Japan Anri Hayashi and Department of Pediatrics, Shiga Medical Center for Children, Shiga, Japan Tatsuya Fujii
 
Corresponding Author : Dr. Kumada
Department of Pediatrics
Shiga Medical Center for Children, Moriyama, Japan
Tel: +81775826200
Fax: +81775826304
E-mail: tkumada@mccs.med.shiga-pref.jp
 
Received March 13, 2013; Accepted June 13, 2013; Published June 20, 2013
 
Citation: Kumada T, Miyajima T, Hiejima I, Nozaki F, Hayashi A, et al. (2013) Modified Atkins Diet and Low Glycemic Index Treatment for Medication-Resistant Epilepsy: Current Trends in Ketogenic Diet. J Neurol Neurophysiol S2:007. doi: 10.4172/2155-9562.S2-007
 
Copyright: © 2013 Kumada T, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
 
Related article at
DownloadPubmed DownloadScholar Google
 
Visit for more related articles at
DownloadJournal of Neurology & Neurophysiology
 
Abstract
 

Compared to the classical ketogenic diet (KD), the modified Atkins diet (MAD) and the low glycemic index
treatment (LGIT) are more liberal and less restrictive diet therapies for the treatment of medication-resistant epilepsy. The MAD was first reported by Kossoff et al. in 2003, and gained global popularity with sufficient evidence in its efficacy reported recently in a controlled study. The LGIT was first reported by Pfeifer et al. in 2005, and its use has also become widespread. We reviewed the efficacy of both diet therapies in the treatment of medication-resistant epilepsy based on the evidence from previous literatures and our own clinical experience. From our experience, the LGIT was more liberal, tolerable, and dietetically balanced than the MAD. To find out which of these diets is most appropriate in different epilepsies and different patients, future controlled comparative studies on the efficacy, tolerability, and dietetic advantages between the MAD and the LGIT are necessary.

 
Keywords
 
Ketogenic diet; Modified Atkins diet; Low glycemic index treatment; Epilepsy
 
Introduction
 
The ketogenic diets (KDs) have been used for the treatment of medication-resistant epilepsy since the 1920s. The classical KD is a highly restrictive diet with a 3:1-4:1 ketogenic ratio, calculated as the weight of fat divided by that of carbohydrates plus protein. Although the classical KD result in at least a 50% reduction in seizure frequency in approximately half of epileptic patients, some patients cannot tolerate the diet over a long period of time because of its restrictiveness. Consequently, the modified Atkins diet (MAD) and the low glycemic index treatment (LGIT) that are more liberal and less restrictive than the classical KD, were developed in the 1990-2000s [1,2]. Contrary to the classical KD, these diets can be provided without restriction of calories, protein and fluid intake, and calculation of ketogenic ratio is not necessary. Figure 1 shows the distribution of major nutrients in calories in each diet [1,2]. MAD and LGIT have a similar composition pattern and the percentage of fat is less than in KD. These new KDs weigh greater importance in having a stable blood glucose level than the production of ketone bodies.
 
Because the KDs including MAD and LGIT are the therapy that the patients and parents must prepare by themselves, the menus of the KDs are greatly affected by their food culture. Thus, the practical menus of these KDs differ among countries based on various local food cultures although the concepts of these KDs are common globally. For example, Japanese patients and parents cannot cook daily KDs menus by referring to the textbooks on the KDs in Western countries because the available foods and the tastes are different between Japan and Western countries. Therefore, we have designed the MAD and LGIT menus which Japanese patients and parents can easily prepare and resemble to normal Japanese ethnic menus.
 
In this paper, we describe the history of development of the KDs, their methods and the evidence of clinical efficacy from the previous literatures. In particular, we present how Japanese patients and parents can cook the MAD and LGIT menus using Japanese ethnic foods concretely in the section of ‘dietary concept, compositon, and menu’ of each diet. We also describe our own clinical experience in each of these diets, and discuss which of these KDs (MAD or LGIT) should be selected in different patients.
 
History of the KDs from fasting to the LGIT
 
An overview of the history of the KDs shows that the focus has changed from a diet that produces ketone bodies efficiently, which mimics fasting, to one that is palatable and can therefore be followed with high compliance. From the period of Hippocrates, it has been known that seizures can be treated by fasting [3]. The KD protocols consisting of high fat and low carbohydrate were designed to mimic the metabolic effect of fasting. In 1921, Geyelin reported to the American Medical Association that the beneficial effect of fasting continued even after the fast was broken. Then, Wilder theorized that the benefit of the diet depends on the ketonemia observed by Geyelin [3,4]. He showed that ketosis occurred when the ratio of fatty acids to glucose was >2:1. From this theory, the classical KD was developed and it was widely used in the treatment of epilepsy. Huttenlocher developed a medium chain triglyceride diet in an attempt to make the classical KD more palatable. With the advancement of the pharmacotherapy for epilepsy, however, the KD treatment has gradually become replaced by antiepileptic drugs, particularly after the introduction of carbamazepine and valproic acid in the 1970-80s.
 
A revival boom of the KDs occurred in the 1990s, starting with an NBC Dateline report in 1994. Soon after, the television movie, "First, Do No Harm", starring Meryl Streep, which was a dramatization of the life of a patient with epilepsy, turned the public’s eye to the diet in 1997. In the last decade, the KDs became popular globally; the 1st international symposium on dietary treatments for epilepsy and other neurological disorders was held in 2008, and the international consensus recommendation was published in Epilepsia in 2009 [5].
 
Meanwhile, Kossoff from Johns Hopkins University Hospital designed and reported on a new and more liberal KD called ‘MAD’ in 2003 [6]. Since then, numerous articles on MAD have been published from all over the world, including USA [7,8], Denmark [9,10], France [11], Belgium [12], Korea [13,14], India [15], Iran [16], and Japan [17]. Separately, in 2005, Pfeifer from Massachusetts General Hospital developed and reported on an alternative ketogenic diet, ‘LGIT’, which was more palatable than the MAD [18]. The diet has also gained a widespread attention. Currently, the MAD and the LGIT are the main KDs used in therapy especially in adolescent and adult patients [19].
 
The MAD
 
Dietary concept, composition and menu
 
The MAD was developed at Johns Hopkins Hospital to create a KD that was more liberal and less restrictive than the classical KD for children who were reluctant to follow the classical KD due to its restrictiveness [1]. Dr. Atkins originally developed the diet in the 1970s as a method for weight reduction for people suffering from obesity. This diet was modified so that the fat intake was increased while the carbohydrate restriction was maintained the same as in the "introduction phase" of the original method. The carbohydrate content of the diet is restricted to 10 g per day at the initiation of the MAD, and is subsequently maintained at 10-30 g per day. Calories, protein and fluids are not restricted. As shown in (Figure 1), the proportion of calories from fat is decreased in the MAD compared to the classical KD. The amount of calories remained from the decrease in fat are assigned to protein so that the ketogenic ratio resulted in 1:1 to 2:1 in the MAD diet. Figure 2a and 2b shows an example of a lunch menu of the MAD in our hospital. The content of carbohydrates, protein, and fat in this menu was 2.5 g, 26.8 g, and 42.8 g respectively, and the ketogenic ratio was 1.46:1, which was lower than that of the classical KD, 3:1 to 4:1.
 
Evidence of efficacy based on previous literatures
 
More than 50 articles on the use of MAD for medication-resistant epilepsy have been published since Kossoff et al. first reported on the diet in 2003, and there is accumulating evidence for its efficacy [5]. Auvin reviewed 7 prospective and 2 retrospective reports, and summarized the efficacy of MAD as follows [20]; the responder rate (the proportion of patients with >50% seizure reduction) was 51/87 (59%) after 1 month, 73/152 (48%) after 3 months, and 46/119 (39%) after 6 months of MAD therapy. Chen et al. investigated the long-term efficacy of the MAD and reported that the responder rate was 64/87 (74%) after 1 month, 36/54 (67%) after 6 months, 28/35 (80%) after 12 months, and 8/16 (50%) after 24 months in intent-to-treat analysis [21]. Recently, a randomized controlled trial of the use of MAD for the treatment of medication-resistant childhood epilepsy published by Sharma et al. [22], showed that the proportion of patients with >90% seizure reduction (30% vs. 7.7%, p=0.005) and that with>50% seizure reduction (52% vs. 11.5%, p<0.001) was significantly higher in the MAD group than in the control group after 3 months. A number of published reports have shown the efficacy of the MAD in specific epilepsy syndromes and underlying diseases including infantile spasms [15], absence epilepsy [23], juvenile myoclonic epilepsy [24], Sturge- Weber syndrome [25], and nonconvulsive status epilepticus [26].
 
Our experience
 
In our group, we have been treating medication-resistant epilepsy with the MAD since 2007. Upon admission, the MAD was initiated with a restriction of the carbohydrate content of the diet to10 g per day, and the total calorie content was adjusted to match the patients’ usual caloric intake before the diet. After 3 to 4 weeks on the diet, we let the parents decide whether or not to continue the diet. We then follow the patients after discharge every 1-3 months at the out-patient clinic.
 
In the current report, we summarized data from 16 patients who started the MAD in our hospital. Table 1 shows the profile and shortterm efficacy and tolerability after 3 months on the diet in all of the patients, including 10 patients reported elsewhere [17]. Eight patients could not continue the diet for more than 3 months. Four of them, including one who was infected with viral gastroenteritis, refused the menus. In the remaining 4 patients, their families gave up preparing the MAD after discharge. Excluding these drop-outs, the efficacy at 3 months was as follows: 3 individuals were excellent responders (seizure-free), 1 was a good responder (>50% seizure reduction), and the diet was not efficacious in the remaining 4. The values of serum beta-hydroxybutyrate were elevated over 2000umol/L at 3 months on the diet in all cases investigated. The long-term efficacy of the MAD in our patients is shown in Figure 3. The responder rate was 4/8 (50%) after 3 months, 3/6 (50%) after 6 months, 3/4 (75%) after 12 months, and 2/4 (50%) after 24 months on the diet. All of 4 patients who completed 24 months of the diet discontinued the diet afterwards. One patient (case- 2) of those who achieved seizure control at the 24 months has been seizure-free since then, although the other patient (case-3) suffered a relapse of seizures soon after the diet was stopped. There were no side effects on the laboratory examinations during the course of the diet except serum total-cholesterol which were slightly elevated (270- 300 mg/dl) in some patients. There were no patients who experienced weight loss or failure of appropriate weight gain during the diet. Severe side effects, which led to an interruption of the MAD occurred in 3 patients: generalized fatigue with severe acidosis (pH 7.20 on blood gas analysis) on the third day of the diet (case-2). Generalized fatigue with unknown cause within 1 week on the diet (case-9), and fainting with hypoglycemia due to refusal of food intake after one month on the diet (case-16). Although case-9 and -16 gave up the restart of the MAD, case-2 could resume the MAD ten days later. Our results suggest that even the MAD has potentially severe life-threatening side effects, especially in the early period from the start of the diet, although many authors have emphasized that the MAD can be safely introduced without hospital admission in contrast to the classical KD [1].
 
The Low Glycemic Index Treatment (LGIT)
 
Dietary concept, composition and menu
 
The glycemic index (GI), designed by Jenkins in 1981 [2], is an indicator of the degree of the increase of blood glucose levels by a specific food as compared to that of a standard food. Low GI foods have since been used for the treatment of diabetes mellitus and obesity.
 
In 2005, Pfeifer et al. from Massachusetts General Hospital first reported on an alternative ketogenic diet, ‘LGIT’ for the purpose of maintaining compliance to diet therapy [18]. This diet allows a more liberal daily intake of carbohydrates (40-60 g per day) than the other KDs, on condition that the GI of carbohydrates is restricted to less than 50 relative to glucose. In the LGIT, a typical proportions of calories are as follows; 60-65% from fat, 20-30% from protein, and 10-15% from carbohydrates (Figure 1). Calories and fluids are not restricted. As a result, the diet is a more palatable and less rigid KD (ketogenic ratio is almost 1:1). The foods do not need to be weighed since the amount is based on portion sizes, which are based on diabetic exchanges.
 
The GI values of foods available in Western countries can be found in the literature [27]. In addition to this report, we used the list of the GI values of Japanese foods prescribed in our previous report [28]. Japanese ethnic foods such as udon (flour noodle), soba (buckwheet noodle), and unpolished Japonica rice mixed with various supplements such as natto (fermented soybeans) and grated yam are all available in the LGIT.
 
Figure 2c shows an example of a lunch menu for the LGIT used in our hospital, in which the total daily calorie intake is 1600 kcal. The carbohydrate used in the lunch was unpolished Japonica rice mixed with natto. The GI value of the unpolished rice is lower than that of polished rice because it has more fiber than its polished counterpart, which can delay the absorption of glucose from the intestine and decrease the speed at which blood glucose increases. Moreover, when mixed with natto, the rate of glucose absorption was reduced, and the GI value of unpolished rice decreases further to fewer than 50 relative to glucose. The content of carbohydrates, protein, and fat in Figure 1c was 22.2 g, 19.3 g, and 39.5 g respectively, and the ketogenic ratio was 0.95:1, which is lower than that of the classical KD and the MAD.
 
Evidence of efficacy based on previous literatures
 
The LGIT was first reported to be effective for the treatment of medication-resistant epilepsy at Massachusetts General Hospital [18]. In their recent report, the responder rate was 42%, 50% ,54% 64%, and 66% at 1, 3, 6, 9 and 12 months after treatment, respectively in intentto- treat analysis [29]. Coppola et al. from Italy showed that 8 of 15 patients (53%) with the LGIT achieved >50% seizure reduction in the first report published outside of Massachusetts General Hospital [30]. Recently, successful treatments with the LGIT for seizures associated with tuberous sclerosis complex [31], Angelman syndrome [32], and mitochondrial disorder [33] have also been reported. However, no controlled studies on the efficacy of the LGIT for the treatment of medication-resistant epilepsy are available. To qualify the evidence for the LGIT, randomized controlled studies are necessary.
 
Our experience
 
We first introduced the LGIT to case-13 in Table 1 because she had refused to comply with the MAD only 2 weeks after the diet therapy even though her seizures remitted with the MAD. She continued to tolerate the LGIT for over 1 year and achieved >50% seizure reduction. Her detailed clinical course with this diet therapy will be published elsewhere [28]. We have tried the LGIT in only 3 patients and no reports other than ours are available in Japan so far. It seems, therefore, that the LGIT has not yet become a popular therapy for medicationresistant epilepsy in Japan. However, we assume that this diet will gain popularity in this country where the rice is a staple food; rice is acceptable with this diet therapy although only unpolished and a small amount of rice were permitted.
 
Which diet should we use, the MAD or the LGIT?
 
Several reports in the literature compared the efficacy of the classical KD and the MAD: Two articles reported a tendency for a higher responder rate with the classical KD than the MAD after 6 months (7/17 vs. 2/10, p=0.41 in Porta et al. [11], 30/50 vs. 13/33, p=0.06 in Miranda et al. [34]), although the differences were not significant. Kossoff et al. reported that patients with Doose syndrome achieved more seizure control by switching from the MAD to the classical KD [35]. In addition, Auvin insisted that the classical KD, not the MAD should be tried in the epileptic emergency such as recent onset of infantile spasms and refractory status epilepticus because the former can resolve the seizures faster [20].
 
Although increasing number of evidences are becoming available that indicates an appropriate choice between the classical KD and the MAD as mentioned above, we still do not have clear answers to govern our choice between the MAD or the LGIT. Our experience with case- 13 in Table 1 who tolerated the LGIT better than the MAD suggested that the LGIT should be considered for patients with medicationresistant epilepsy who cannot tolerate more restrictive diet therapies. On the other hand, there has not been any comparative data from the dietetic perspective between the MAD and the LGIT. Figure 4 shows the micronutrient distribution in the MAD and the LGIT given to case-13 at our hospital. The % dietary reference intakes (%DRI) of all of the minerals and soluble vitamins listed were higher in the LGIT than in the MAD. Furthermore, among all of the subjects, the %DRI of some soluble vitamins (B2, C, and folate) was >100% in the LGIT, making supplementation unnecessary. Therefore, we believe that the LGIT would be superior to the MAD based on its tolerability and dietetic balance. However, we do not have data from a controlled trial or retrospective analysis, comparing the efficacy of the MAD and the LGIT.
 
Conclusion
 
Currently, there is a large volume of evidence, including one controlled trial, on the efficacy of the MAD for seizure control, and the diet was established as an important treatment for medicationresistant epilepsy. In contrast, there is less evidence for use of the LGIT without any controlled trials. This therapy is less popular than the MAD, especially in Japan. Further comparative data on the efficacy, tolerability and dietetic balance of both the MAD and the LGIT are needed in order to select the best type of diet therapy for patients with medication-resistant epilepsy.
 
Acknowledgements
 
We gratefully thank Miyuki Takada, the dietitian of our hospital, for designing the MAD and LGIT menus. The authors report no conflicts of interest.
 
References
 



































 


 View 

 Download    pdf version of this article

References




































Tables at a glance

Table 1


Figures at a glance

     
Figure 1  Figure 2  Figure 3  Figure 4
Select your language of interest to view the total content in your interested language
 
Share This Article
   
 
   
 
Relevant Topics
Disc ADHD
Disc AIDS-associated Dementia
Disc Adult Bipolar Disorder Clinical Psychopharmacology
Disc Adult Bipolar Disorder: Mixed features
Disc Adult Bipolar Disorders: Cyclothymia
Disc Advance Treatment for Multiple Sclerosis
Disc Advanced Parkinson Treatment
Disc Advances in Alzheimers Therapy
Disc Advances in autism diagnosis
Disc Alcohol Addiction
Disc Alcoholic Neuropathy
Disc Alzheimers Medicine
Disc Alzheimers Products & Market Analysis
Disc Alzheimers Symptoms
Disc Amyotrophic lateral sclerosis
Disc Anticonvulsants
Disc Anxiety
Disc Applied behaviour analysis
Disc Asperger's syndrome
Disc Aura
Disc Autism Spectrum Disorders
Disc Autism in children
Disc Autism theraphy
Disc Backache
Disc Bacteria Induced Neuropathies
Disc Biomechanics of Spine
Disc Bipolar Affective
Disc Bipolar Affective Disorders
Disc Bipolar Disorder Facts
Disc Bipolar Disorder Treatment
Disc Bipolar Disorder in Adults
Disc Bipolar Disorder in Children
Disc Bipolar Disorder in Women
Disc Bipolar II Disorder
Disc Bipolar Psychosis
Disc Brain Aneurysm
Disc Brain Epilepsy
Disc Brain Infection
Disc Brain Injury Rehabilitation
Disc Brain Mapping
Disc Brain Rehabilitation
Disc Brain Scan
Disc Brain Stem Cell Therapy
Disc Brain Stimulation
Disc Brain Stroke
Disc Brain Structure and Function
Disc Brain Trauma/ Injury
Disc Brain Tumor
Disc Brain Tumors
Disc CNS and Neurological Disorders
Disc Cerebral Palsy
Disc Cervical Laminectomy
Disc Childhood Anxiety
Disc Childhood Disorders
Disc Childhood Epilepsy
Disc Chronic Health Conditions
Disc Clinical Epilepsy
Disc Clinical Neuroimmunology
Disc Cognition
Disc Cognitive Disorders
Disc Cognitive Science
Disc Coma
Disc Convulsion
Disc Degenerative Disorders
Disc Demyelination
Disc Dendritic Cell Immunology
Disc Depression
Disc Depression and Aging
Disc Diagnosing Bipolar Disorder
Disc Diagnosis of Autism
Disc Diagnostic Alzheimer
Disc Disseminated Sclerosis
Disc DrugAddiction
Disc Dysthemia
Disc Electroencephalography
Disc Encephalitis
Disc Encephalomyelitis Disseminate
Disc Epilepsy
Disc Epilepsy - Neurological disorder
Disc Epilepsy Syndromes
Disc Epilepsy neurorehabilitation
Disc Essential Tremor
Disc Experimental Neurology
Disc Focal Epilepsy
Disc Frontal Lobe Epilepsy
Disc Fungal Infection
Disc Germ cell tumours
Disc Health Promotion
Disc Health-Related Quality of Life
Disc Hippocampus
Disc Huntington's Disease
Disc Hydrocephalus
Disc Hypothalamus
Disc Immune-Mediated Disease
Disc Immunocytochemistry
Disc Infectious Disease in Children
Disc Intellectual Disability
Disc Ischemic Stroke
Disc Ischial Spine
Disc Lamictal Bipolar Disorder
Disc Laminectomy
Disc Limbic System
Disc Lower Back Pain
Disc Lower Back Surgery
Disc Lyme
Disc Manic Despondency
Disc Manic-Depressive illness
Disc Medical Education
Disc Medical Rehabilitation
Disc Medicare
Disc Medication for Bipolar Disorder
Disc Mental Disorder
Disc Mental Health Illiteracy
Disc Mental Health Morbidity
Disc Mental Health Needs
Disc Mental Health Services
Disc Mindfullness Based Therapy
Disc Minimal Invasive Spine Surgery
Disc Mood Disorder
Disc Mood Disorders
Disc Motor Neuron Disease
Disc Multiple Sclerosis
Disc Multiple Sclerosis Diagnosis
Disc Multiple Sclerosis Physical Therapy
Disc Multiple sclerosis (MS) Medications
Disc Myasthenia Gravis
Disc Myelin Repair
Disc Nerve Injury
Disc Neural Model
Disc Neuro Rehabilitation
Disc Neuro-HIV and Bacterial Infection
Disc Neuro-Infections Induced Autoimmune Disorders
Disc Neurocystercercosis
Disc Neurocysticercosis
Disc Neurodegenerative Diseases
Disc Neurodegenerative Disorders
Disc Neuroendocrine Immunology
Disc Neuroepidemiology
Disc Neuroimmunological Disorders
Disc Neuroinfectious Agents
Disc Neuroinflammation
Disc Neurointensive Care
Disc Neurological Disabilities
Disc Neurological Physiotherapy
Disc Neurological Rehabilitation
Disc Neurological disorders
Disc Neuromuscular Disorders
Disc Neuromyelitis Optica
Disc Neuronal processing
Disc Neurooptometric Rehabilitation
Disc Neuropathy
Disc Neuropsychiatry
Disc Neurorehabilitation
Disc Neurorehabilitation Psychotherapy
Disc Neurorehabilitation and Neural Repair
Disc Neurosurgery
Disc Neurosurgical Emergencies
Disc Neurosyphilis
Disc Neurovirology
Disc Nocturnal Epilepsy
Disc Obsessive Compulsive Disorder
Disc Occupation therapy for autism
Disc OccupationalTherapy
Disc Panayiotopoulos Syndrome
Disc Panic Attacks
Disc Parkinson
Disc Parkinson's Disease
Disc Parkinsonism Diagnosis
Disc Parkinsonism Gene Therapy
Disc Parkinsonism Stages and Treatment
Disc Pathophysiology
Disc Pathophysiology of Bipolar Disorder
Disc Pediatric Bipolar Disorder
Disc Pediatric Epilepsy
Disc Photosensitive Epilepsy
Disc Pituitary
Disc Post Traumatic Disorders
Disc Postictal State
Disc Progressive Multifocal Leukoencephalopathy
Disc Pseudohypertrophic Myopathy
Disc Rapid Cycling Bipolar Disorder
Disc Rare Infectious Disease
Disc Repetitive Behaviours in Autism
Disc Rett syndrome
Disc Rolandic Epilepsy
Disc Schizoaffective Disorder Bipolar Type
Disc Schizophrenia- Psychotic disorder
Disc Sciatic nerve
Disc Sciatica
Disc Scoliosis
Disc Seizure
Disc Seizure Disorder
Disc Seizure Medications
Disc Severe Bipolar Disorder
Disc Shaking Palsy
Disc Signs of Bipolar Disorder
Disc Social Anxiety Disorder
Disc Social Stigma
Disc Social communication
Disc Spina bifida
Disc Spinal Canal
Disc Spinal Cord
Disc Spinal Cord Injury Rehabilitation
Disc Spinal Diseases
Disc Spinal Stenosis
Disc Spine
Disc Spine Cancer
Disc Spine Research
Disc Spine Surgery
Disc Spine Tumour
Disc Spine pediatrics
Disc Spondylosis
Disc Stem cell Treatment Parkinson
Disc Stress Disorder
Disc Stroke Disorder
Disc StrokeRehabilitation
Disc Suicidal Thoughts
Disc Symptoms of Bipolar Disorder
Disc Techniques in Spine surgery
Disc Temporal Lobe Epilepsy
Disc The Autistic Brain
Disc Toxoplasmosis
Disc Traumatic Brain Injury
Disc Treatment Effects
Disc Vaccines and autism
Disc Viral Infection
 
Related Journals
Disc Alzheimers Journal
Disc Autism Journal
Disc Bipolar Disorder Journals
Disc Brain Disorders & Therapy Journal
Disc Depression and Anxiety Journal
Disc Epilepsy Journal
Disc Mental Disorders Journal
Disc Multiple Sclerosis Journal
Disc Neuroimmunology Journal
Disc Neuroinfectious Diseases Journal
Disc Neurological Disorders Journal
Disc Neurorehabilitation Journal
Disc Neurosciences Journal
Disc Neurosurgery Journals
Disc Spine Journal
Disc Spine Research Journal
Disc Stroke Journal
 
Related Conferences
Disc

7th Neurologists Meeting on Neurology and Neurosurgery
August 22-24 2016 Vienna, Austria

Disc 4th Conference on Neuropharmacology  
Sept 15-17, 2016 San Antonio, USA
Disc

5th Alzheimer’s disease and Dementia Conference
September 29-October 01, 2016 London, UK

Disc Epilepsy Conference
October 20-21, 2016 Rome, Italy
Disc 10thInternational Conference on Nursing and Healthcare
December 05-07, 2016 Dallas, USA
 
Article Tools
Disc Export citation
Disc Share/Blog this article

Post your comment

Name:
E-mail:
Your question:
Anti Spam Code:
  Reload  Can't read the image? click here to refresh

OMICS International Conferences 2016-17

Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings
Conferences By Country
  USA   Spain   Poland
  Australia   Canada   Austria
  UAE   Switzerland   Turkey
  Italy   France   Finland
  Germany   India   Ukraine
  UK   Malaysia   Denmark
  Japan   Singapore   Mexico
  Brazil   South Africa   Norway
  South Korea   New Zealand   China
  Netherlands   Philippines
 
Medical & Clinical Conferences
Microbiology Oncology & Cancer
Diabetes & Endocrinology Cardiology
Nursing Dentistry
Healthcare Management Physical Therapy Rehabilitation
Neuroscience Psychiatry
Immunology Infectious Diseases
Gastroenterology Medical Ethics & Health Policies
Genetics & Molecular Biology Palliativecare
Pathology Reproductive Medicine & Women Healthcare
Alternative Healthcare Surgery
Pediatrics Radiology
Ophthalmology  
 
Conferences by Subject
Pharmaceutical Sciences
Pharma Marketing & Industry
Nutrition
Environmental Science
Physics & Materials Science
Environmental
EEE & Engineering
Veterinary
Chemical Engineering
Business Management
Massmedia
Geology & Earth science
 
 
©2008-2016 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version